Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities
CHAPEL HILL, N.C., July 22, 2011 /PRNewswire/ -- The structure of a biopharmaceutical company's Internal Communications group must evolve to reflect the changing goals and strategies. Realigning to support new corporate initiatives and establishing service levels to reflect priorities and resources are key improvement areas for Internal Communications executives in 2012.
"Differentiated services hold great value during times of resource reductions," according to "Internal Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC.
Download a complimentary white paper at http://www3.best-in-class.com/rr1094.htm that includes selected best practices drawn from extensive primary research with executives from 26 leading biopharmaceutical and medical device companies. The full 61-page report contains more than 100 benchmark metrics and 20 executive narratives, providing communications executives with organizational models and trends and insights about structure, staffing and investment levels.
Key insights include:
- In the Pharma Segment, 52 percent of Internal Communications executives noted their group has a business unit focus while 48 percent have an enterprise-wide focus. Only 14 percent noted a product focus for the Internal Communications group.
- While a majority of both biopharma and other industries favor a centralized approach for Internal Communications, a third of both takes a regional approach, where staff are placed in major regional offices (although a central group still resides at headquarters).
In conjunction with this study, "External Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Bes